Tissue Chip Research Consortium Membership

The purpose of this Purchase Order is to obtain a membership in the TAMU Tissue Chip Consortium. The Tissue Chip Consortium is for Human-relevant complex in vitro modeling systems, often referred to as “tissue chips” which is a rapidly developing area of technology that offer great promise for advancing the ability of the National Toxicology Program to be more predictive and responsive to regulators and other stakeholders.  As a rapidly developing technology, it is difficult and inefficient for any one organization to gain sufficient experience with the technology to understand how to apply it most effectively. Partnership with other stakeholders and an academic center with the capability to evaluate the functionality and reproducibility of a portfolio of these systems via membership in a tissue chip consortium, allows the for the efficient advance of understanding of this technology and ability to apply it. The application of tissue chips, also termed organ-on-a-chip technologies) is consistent with Theme 1 Goal 6 of the NIEHS strategic plan: Advancing Environmental Health Sciences; Predictive Toxicology: Predictive toxicology remains a priority component of EHS. This approach takes advantage of basic knowledge of biological pathways to build a set of targeted, human-relevant computational, in silico, in vitro, or animal tests to predict adverse effects of a chemical exposure. Predictive toxicology advances include organ-on-a-chip technologies and systems biology platforms, among others.

This notice of intent is not a solicitation or request for quotes. Notwithstanding, any firm that believes it is capable of meeting NIEHS’ requirement, as stated herein, may submit their corporate capabilities, which, if received by the response date of this announcement, may be considered.  Responses to this posting must be in writing and shall be emailed to Christopher Fisher at Christopher.fisher@nih.gov and are due by 1:00PM ET on April 21, 2020.